Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 12, 2024 (3 years ago)

Infumorph (Preservative-free Morphine Sulfate Sterile Solution)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

The filter included in the carton has an expiration date that has expired prior to the expiration date of the actual product lot.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Infumorph (Preservative-free Morphine Sulfate Sterile Solution), 20 mL ampul, Rx only, Manufactured by Hikma Berkeley Heights, NJ 07922, NDC 0641-6039-01

Affected NDC 0641-6039-01

Compare with the code on your package — it is the most precise check available.

Drug: Morphine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Infumorph 200
morphine sulfate
NDC 00641-6039
10 mg/mL Injection, Solution
Epidural|intrathecal
Hikma Pharmaceuticals USA Inc. Rx · CII
Recalling firm
Hikma Pharmaceuticals USA Inc.
NDC code
0641-6039-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0392-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Morphine recalls

See all
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026

Other recalls by Hikma Pharmaceuticals USA Inc.

All 2024 recalls
Class II · Moderate risk

Ramipril Capsules USP

Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Ongoing Impurity / degradation Hikma Pharmaceuticals USA INC. NDC 76282-673-01 D-0831-2026
Class II · Moderate risk

Alendronate Sodium Oral Solution

This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.

Ongoing Wrong potency / content Hikma Pharmaceuticals USA INC NDC 0054-0282-59 D-0526-2026
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Ongoing Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class I · High risk

Acetaminophen Injection

Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

Ongoing Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9386-01 D-0635-2024